Vanda Pharmaceuticals EV/EBIT VNDA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2018.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 18.1×; Dec 2022
8-year median: 16.4×
8-year range: 3.2× to 133×
Peer median: 4.9×

Vanda Pharmaceuticals has no meaningful EV/EBIT today: it made an operating loss of $185.7M over the last twelve months.

It was last meaningful in Dec 2022, at 18.1×.

On the days it had one over the last 8 years, its median was 16.4×, from 3.2× in Apr 2022 to 133× in Jan 2019.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	18.1×	3.2×	20.8×
2021	10.9×	10.9×	24.7×
2020	18.2×	6.8×	22.9×
2019	24.2×	17.8×	133×
2018	106×	96.6×	116×

Against its peers

Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
VNDAVanda Pharmaceuticals	n/m
NATRNatures Sunshine Products	5.2×
ARVNArvinas	n/m
PBYIPuma Biotechnology	15.6×
IRWDIronwood Pharmaceuticals	3.5×
ZVRAZevra Therapeutics	2.9×
CRMDCorMedix	2.3×
COLLCollegium Pharmaceutical	9.4×
LFVNLifevantage	9.6×
ABUSArbutus Biopharma	4.9×
SPROSpero Therapeutics	2.1×
Peer median	4.9×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Vanda Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.